|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Adenoma, multiple endocrine |
|
Esophagitis, erosive |
|
Gastroesophageal Reflux Disease |
|
Hemorrhage, upper gastrointestinal, prophylaxis |
|
Mastocytosis, systemic |
|
Ulcer, duodenal |
|
Ulcer, gastric |
|
Zollinger- Ellison syndrome |
| |
|
|
SIDE EFFECTS:
|
|
acneiform rash |
|
agitation |
|
agranulocytosis |
|
anaphylactoid reactions |
|
angioedema |
|
anxiety |
|
arthralgia |
|
AV block |
|
bronchospasm |
|
confusion |
|
depression |
|
diarrhea |
|
dizziness |
|
elevated hepatic enzymes |
|
exfoliative dermatitis |
|
galactorrhea |
|
gynecomastia |
|
hallucinations |
|
headache |
|
hepatitis |
|
hyperprolactinemia |
|
impotence |
|
infection |
|
jaundice |
|
leukopenia |
|
libido decrease |
|
maculopapular rash |
|
myalgia |
|
neutropenia |
|
pancreatitis |
|
pancytopenia |
|
premature ventricular contractions (PVCs) |
|
sinus bradycardia |
|
sinus tachycardia |
|
Stevens-Johnson syndrome |
|
thrombocytopenia |
|
toxic epidermal necrolysis |
|
urticaria |
|
vasculitis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
breast-feeding |
|
children |
|
elderly |
|
gastric cancer |
|
2-blocker*hypersensitivity#243"H2-blocker hypersensitivity |
|
hepatic disease |
|
immunosuppression |
|
infection |
|
intravenous administration |
|
pregnancy |
|
renal failure |
|
renal impairment |
|
|
ADULT DOSE:
|
|
Duodenal ulcer or
Gastric ulcer or
Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas) or
Upper gastrointestinal bleeding-Intramuscular, 300 mg (base) every six to eight hours.
Intravenous, 300 mg (base) every six to eight hours, diluted with a compatible intravenous solution and administered over a period of not less than five minutes.
Intravenous infusion, 300 mg (base) every six to eight hours, diluted in a compatible intravenous solution and administered over a fifteen- to twenty-minute period.
Note: If necessary, increases in dosage should be made by more frequent administration of a 300-mg dose.
Continuous intravenous infusion, 37.5 (base) mg per hour (900 mg per day), diluted in a compatible intravenous solution. The infusion rate should be adjusted to individual patient requirements.
Note: For patients requiring a rapid elevation of gastric pH, a loading dose of 150 mg may be administered by intravenous infusion before continuous infusion is begun.
Prophylaxis of stress-related mucosal bleeding-Continuous intravenous infusion, 50 mg (base) per hour, diluted in a compatible intravenous solution for up to 7 days.
Note: Patients with a creatinine clearance less than 30 mL per minute should receive 25 mg per hour.
[Prophylaxis of aspiration pneumonitis]-Intramuscular, 300 mg (base) one hour before induction of anesthesia, and 300 mg (base) given intramuscularly or intravenously every four hours until patient responds to verbal commands.
[Urticaria therapy adjunct]-Intravenous, 300 mg over 15 to 20 minutes.
Note: For patients with impaired renal function-Intravenous, 300 mg (base) every twelve hours, the dosage being increased to 300 mg every eight hours or more frequently, if necessary. Further reduction in dosage may be required if hepatic function impairment is also present. |
|
MAXIMUM ADULT DOSE:
|
|
2.4 grams (base) daily.
|
|
PEDIATRIC DOSE:
|
|
Duodenal ulcer or
Gastric ulcer-Intramuscular, 5 to 10 mg (base) per kg of body weight every six to eight hours.
Intravenous, 5 to 10 mg (base) per kg of body weight every six to eight hours, diluted to a suitable volume with a compatible intravenous solution and administered over a period of not less than two minutes.
Intravenous infusion, 5 to 10 mg (base) per kg of body weight every six to eight hours, diluted to a suitable volume with a compatible intravenous solution and administered over a fifteen- to twenty-minute period.
Note: In certain circumstances, doses may be titrated based on gastric pH.
Clinical experience with the use of cimetidine in children up to 16 years of age is limited; risk-benefit must be considered.
In children with impaired renal function, doses should be reduced and dosing interval increased. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Duodenal ulcer or
Gastric ulcer or
Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas) or
Upper gastrointestinal bleeding-Intramuscular, 300 mg (base) every six to eight hours.
Intravenous, 300 mg (base) every six to eight hours, diluted with a compatible intravenous solution and administered over a period of not less than five minutes.
Intravenous infusion, 300 mg (base) every six to eight hours, diluted in a compatible intravenous solution and administered over a fifteen- to twenty-minute period.
Note: If necessary, increases in dosage should be made by more frequent administration of a 300-mg dose.
Continuous intravenous infusion, 37.5 (base) mg per hour (900 mg per day), diluted in a compatible intravenous solution. The infusion rate should be adjusted to individual patient requirements.
Note: For patients requiring a rapid elevation of gastric pH, a loading dose of 150 mg may be administered by intravenous infusion before continuous infusion is begun.
Prophylaxis of stress-related mucosal bleeding-Continuous intravenous infusion, 50 mg (base) per hour, diluted in a compatible intravenous solution for up to 7 days.
Note: Patients with a creatinine clearance less than 30 mL per minute should receive 25 mg per hour.
[Prophylaxis of aspiration pneumonitis]-Intramuscular, 300 mg (base) one hour before induction of anesthesia, and 300 mg (base) given intramuscularly or intravenously every four hours until patient responds to verbal commands.
[Urticaria therapy adjunct]-Intravenous, 300 mg over 15 to 20 minutes.
Note: For patients with impaired renal function-Intravenous, 300 mg (base) every twelve hours, the dosage being increased to 300 mg every eight hours or more frequently, if necessary. Further reduction in dosage may be required if hepatic function impairment is also present. |
|
|
|
|
|